Giraffe Bio key facts
- Developer of a biomining technology designed to improve the efficiency and sustainability of metal extraction.
- It has raised $60K; the latest was Early Stage VC in Dec 2025.
- Notable investors include SOSV, Start-Up Chile, The Think & Act Differently, AIR Capital, Columbia Business School — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch Giraffe Bio: the Monday email on marks, rounds and moves
Giraffe Bio funding rounds
No funding rounds for Giraffe Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Giraffe Bio investors
6 investors are on record for Giraffe Bio, including SOSV, Start-Up Chile, The Think & Act Differently and AIR Capital.
About Giraffe Bio
Developer of a biomining technology designed to improve the efficiency and sustainability of metal extraction. The company offers AI-optimized biomolecule engineering, cell-free systems and proprietary screening tools, enabling mining companies working with low-grade or complex ores to increase metal yields, reduce environmental impact, and lower operational costs.
- Sector
- Information Technology
- HQ
- Buenos Aires, Argentina
- Founded
- 2024
- Employees
- 7
- Website
- giraffe-bio.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.
Giraffe Bio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.